Cargando…

Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism

Temozolomide (TMZ) is used for the treatment of high-grade gliomas. Acquired chemoresistance is a serious limitation to the therapy with more than 90% of recurrent gliomas showing little response to a second line of chemotherapy. Therefore, it is necessary to explore an alternative strategy to enhan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Delong, Jin, Guoqing, He, Hong, Zhou, Wei, Fan, Zhenbo, Gong, Chen, Zhao, Jing, Xiong, Huihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457578/ https://www.ncbi.nlm.nih.gov/pubmed/34497154 http://dx.doi.org/10.18632/aging.203443

Ejemplares similares

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma
por: Yang, Eryan, et al.
Publicado: (2022)

Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation
por: Tsai, Yu-Ting, et al.
Publicado: (2022)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas
por: Yin, Jianxing, et al.
Publicado: (2023)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma
por: Chien, Chia-Hung, et al.
Publicado: (2022)

A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
por: Gilbert, Mark R., et al.
Publicado: (2010)

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
por: Kast, Richard E., et al.
Publicado: (2014)

MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
por: Tian, Tian, et al.
Publicado: (2016)

MicroRNA-138 Increases Chemo-Sensitivity of Glioblastoma through Downregulation of Survivin
por: Yoo, Ji-Young, et al.
Publicado: (2021)

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma
por: Gong, Lingli, et al.
Publicado: (2022)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells
por: Zhang, Huaijin, et al.
Publicado: (2023)

Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017)

Integrated genetic and metabolic landscapes predict vulnerabilities of temozolomide resistant glioblastoma cells
por: Immanuel, Selva Rupa Christinal, et al.
Publicado: (2021)

Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
por: Yin, An-An, et al.
Publicado: (2019)

20(S)‐ginsenoside‐Rg3 reverses temozolomide resistance and restrains epithelial‐mesenchymal transition progression in glioblastoma
por: Chen, Zheng, et al.
Publicado: (2018)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
por: Yu, Jian, et al.
Publicado: (2022)

GSK3β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2–STAT3 axis
por: Zhao, Chenggang, et al.
Publicado: (2022)

Tbx2 confers poor prognosis in glioblastoma and promotes temozolomide resistance with change of mitochondrial dynamics
por: Yi, Fuxin, et al.
Publicado: (2017)

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Zampieri, Luca X., et al.
Publicado: (2021)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide
por: Cuperlovic-Culf, Miroslava, et al.
Publicado: (2014)

Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma
por: Tiek, D. M., et al.
Publicado: (2018)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide
por: Zimmerman, Mary A, et al.
Publicado: (2020)

BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53
por: Nie, Er, et al.
Publicado: (2016)

Relation between autophagy and the resistence of glioblastoma cells to temozolomide
por: Carmo, Anália, et al.
Publicado: (2010)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

Aspergillosis in a Patient Receiving Temozolomide for the Treatment of Glioblastoma
por: Munhoz, Rodrigo Ramella, et al.
Publicado: (2013)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
por: Stepanenko, Aleksei A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0lhhcu6o2sbe14n4uhph4f34pi